Dear Reader,
The IMF doesn't issue warnings like this often, but when they do... you need to listen.
For your entire life, debt crises have always happened anywhere but America.
Italy in the 90s. Argentina in 2001. Greece in 2009.
America was always safe… until now.
The IMF projects that by 2030, US debt will climb to 140% of GDP.
That's higher than Greece's debt was when their entire economy collapsed.
When Greece broke, the EU swooped in with $300 billion in emergency bailouts. Greece was OK.
But when America crosses that line? There's no one bigger to save us. We ARE the emergency bailout for the rest of the world.
Watch how this group of 4,000 investors is preparing →
Here's what happened in Greece when the system broke…
Retirees' pensions got slashed 40% overnight.
People who saved for 40 years, who followed all the rules, watched their retirement go up in smoke.
And it only took 24 months.
We're following their exact playbook right now.
I'm Tan Gera, ex-Wall Street investment banker and CFA Charterholder.
I walked away because I saw how the system really works.
Banks protect themselves first. Politicians kick the can. And regular folks like you are left holding the bag.
That's why my team now helps over 4,000 investors build what we call a "financial firewall"...
A parallel savings system that operates completely outside the Federal Reserve's control.
You can't fix $38 trillion in debt. You can't stop Congress from spending. But you CAN control how much of your wealth stays exposed to the fallout.
Click here to watch the free presentation →
This video won't be online forever because banks don't want you thinking about alternatives.
To your sovereignty,
Tan Gera, CFA
Decentralized Masters
P.S. The window is closing. Greece went from stable to collapsed in 24 months. Watch the presentation now while you still can →
Coursera's Options Anomaly: A Big Bet on What's Next?
Author: Jeffrey Neal Johnson. Article Published: 3/30/2026.
Key Points
- The pending merger of Coursera with Udemy will create a dominant global learning platform with significant opportunities for increased profitability and cost savings.
- Coursera is leveraging its vast user data to transform into an AI-native technology company, creating a powerful moat in the educational tech space.
- A recent spike in bullish options activity indicates that sophisticated traders may be positioning for a major positive catalyst on the horizon.
- Special Report: Elon’s “Hidden” Company
A stark divergence is unfolding in the market for Coursera (NYSE: COUR). On the surface the story looks bearish: the online learning platform’s stock closed at $5.52 at the end of March’s last trading week, down 5.65% for the week and sitting near its 52-week low of $5.47. For many investors, that price action is a clear signal to steer clear.
But beneath the surface, in the derivatives market, a very different story is playing out. This is where sophisticated traders place their most forward-looking bets. While Coursera’s share price flirted with 52-week lows, call option volume on Coursera surged 1,591% above its daily average.
Trump’s Craziest Profanity-Laced Post Yet – Here’s Why He Did It (Ad)
When Trump posted something shocking on Sunday, the media called him out of control. But according to Addison Wiggin, Founder of Grey Swan Investment Fraternity, there is a deliberate strategy behind it.
Wiggin says the real reason is controversial - and most people are missing it entirely.
Discover the strategy behind Trump's most talked-about postSuch a sudden influx of activity is unlikely to be random noise; it more likely reflects a concentrated bet that the stock is poised for a material move higher.
That raises an important question for investors: what do these traders see that the broader market may be overlooking?
Why This Options Spike Is a High-Stakes Signal
A dramatic jump in options activity is rarely coincidental and can be a leading indicator of a stock’s future direction. A call option gives its buyer the right to purchase shares at a set price, effectively betting on a rise in the underlying stock. Options offer leverage: a relatively small outlay can control a large position, amplifying potential gains.
Volume matters. While open interest shows the total number of outstanding contracts, a massive surge in volume signals that new money is rushing into the trade. The scale of the recent activity points to large institutions or other informed players placing those bets. These traders deploy significant capital based on in-depth research, and their decisive moves often precede major corporate events or shifts in market perception that are not yet public.
The One-Two Punch: Catalysts for a Comeback
The institutional positioning in Coursera appears to rest on two potential, game-changing catalysts that could force a market re-rating.
The most visible catalyst is the pending all-stock merger with Udemy (NASDAQ: UDMY). The combined company would create a major player in online learning, with a global user base of roughly 300 million learners and pro forma revenue of about $1.5 billion. Strategically, the deal pairs Coursera’s university-accredited content with Udemy’s large library of practical, vocational courses.
Critically for investors, management expects $115 million in annual run-rate cost savings, which would materially improve margins. The unusual options activity could indicate traders positioning ahead of positive merger developments — for example, faster-than-expected regulatory approval or upward revisions to projected cost savings.
The Market Is Missing the AI Transformation
Beyond the merger, Coursera is evolving from a content platform into an AI-native technology company. Its large dataset — drawn from the learning patterns, quiz results and skill tracking of roughly 197 million users — provides a defensible advantage for training proprietary models.
Coursera is rolling out AI features such as personalized coaching tools and deepening partnerships with providers like Google and Anthropic. Demand for AI skills is surging: learners reportedly enrolled in Coursera’s generative AI courses at a rate of about 15 learners per minute in 2025. The recent bullish bets could be anticipating a major AI-driven product launch or another milestone that forces Wall Street to view Coursera as a leader in global AI reskilling rather than a legacy education platform.
Finding Value Where Others See Risk
Coursera’s recent price performance has been weak, and that depressed pricing is central to the bullish case. With a market capitalization under $1 billion, the company’s valuation looks disconnected from its scale and prospects. Coursera trades at a price-to-sales ratio near 1.23, a multiple that appears low compared with many platform technology peers.
That low valuation has two implications. First, Coursera becomes an attractive target for private equity or strategic acquirers seeking an entry into EdTech. Second, at this price, institutions can use call options to control large numbers of shares for a relatively small upfront cost, creating the potential for outsized returns if a positive catalyst occurs. The stock can be viewed as a coiled spring, and sophisticated traders seem to be betting on a release of that tension.
Connecting the Dots
When the options market sends a signal this strong, investors pay attention. The 1,591% surge in call volume is a footprint of institutional capital and suggests conviction that a meaningful positive event may be coming. Although past insider selling warrants caution, institutional ownership is high — nearly 90% — and this fresh wave of bullish bets indicates the smart money may see a turning point.
The catalyst is not yet public, but investors should monitor a few key areas closely:
- New SEC filings or regulatory updates tied to the Udemy merger.
- Official announcements about Coursera’s AI platform, product launches, or partnerships.
- Rumors or developments suggesting a buyout or strategic acquisition interest.
The options market is not infallible, but a 1,591% surge in call volume is unlikely to be random. Something is drawing institutional capital into Coursera, and that answer may surface soon.
Merck Just Made a Big Bet on a New Cancer Growth Engine
Author: Jessica Mitacek. Article Published: 3/31/2026.
Key Points
- Merck is set to acquire Terns Pharmaceutical for $6.7 billion, adding its promising leukemia treatment to its growing hematology and cancer pipeline.
- This is Merck’s third multi-billion dollar deal in a year, a bolt-on strategy projected to drive a $70 billion commercial opportunity by the mid-2030s.
- With an average five-year gross margin of 73% and 14 consecutive years of dividend increases, Merck remains a top-tier performer with a Moderate Buy rating.
- Special Report: Elon’s “Hidden” Company
While the health care sector has struggled this year, that hasn’t been the case for all of Big Pharma.
Shares of New Jersey-based Merck & Co. (NYSE: MRK) have outperformed the sector and the broader market, rising more than 12%.
Trump’s Craziest Profanity-Laced Post Yet – Here’s Why He Did It (Ad)
When Trump posted something shocking on Sunday, the media called him out of control. But according to Addison Wiggin, Founder of Grey Swan Investment Fraternity, there is a deliberate strategy behind it.
Wiggin says the real reason is controversial - and most people are missing it entirely.
Discover the strategy behind Trump's most talked-about postThe drugmaker’s stock recently rallied after news it will acquire Terns Pharmaceuticals—a deal that strengthens its cancer-treatment pipeline and underscores Merck’s reputation as a serial acquirer.
This M&A activity has helped drive Merck’s steady growth and market-cap expansion: its market value now tops $296 billion, behind only Eli Lilly (NYSE: LLY) and AbbVie (NYSE: ABBV), at roughly $830 billion and $370 billion, respectively.
Merck’s Terns Acquisition Is a Pivotal Oncology Play
On March 25, Merck announced it had reached an agreement to acquire Terns, a clinical-stage oncology company developing therapies including TERN-701, an oral allosteric BCR–ABL1 inhibitor for chronic myeloid leukemia (CML).
According to the press release, Merck will acquire Terns for $53 per share in cash, valuing the company at about $6.7 billion. Merck said the deal further builds its hematology franchise with a “potential best-in-class candidate for the treatment of certain patients with chronic myeloid leukemia.”
The definitive agreement marks Merck’s third multi-billion-dollar acquisition in the past year. Though still clinical-stage, TERN-701 has shown “encouraging rates of molecular response and deep molecular response,” including in patients with high disease burden who previously received multiple lines of therapy.
M&A Activity Has Helped Support Merck’s Earnings and Dividend Profile
Securing the Terns deal highlights Merck’s central role in the pharmaceutical industry, which has translated into a strong earnings track record. The company has missed analyst estimates only once in the past 19 quarters, dating back to Q2 2021.
When Merck reported Q4 2025 financials on Feb. 3, it posted earnings per share (EPS) of $2.04, beating expectations of $2.01, and revenue of $16.40 billion, topping forecasts of $16.19 billion. With a forward price-to-earnings multiple of about 16.45, Merck’s EPS is forecast to grow nearly 10% over the next year, from $9.01 to $9.90.
In his earnings-call remarks, CEO Rob Davis attributed the company’s steady growth to new product launches, progress in key clinical programs, and added scale in respiratory and infectious diseases from the Verona Pharma and Cidara Therapeutics acquisitions.
"As a result of this progress, we now have line of sight to over $70 billion of potential commercial opportunity by the mid-2030s, $20 billion more than just a year ago and more than double consensus 2028 peak Keytruda revenue of $35 billion," Davis said.
While those revenue projections are attractive to shareholders and potential investors, the key takeaway is the rapid scale Merck routinely achieves through its acquisition strategy.
That M&A activity—including the Verona Pharma and Cidara Therapeutics deals, valued at $10 billion and $9.2 billion respectively—was followed by the Terns announcement, valued at about $6.7 billion.
Merck continues to emphasize a bolt-on acquisition strategy to diversify its oncology, immunology, and infectious-disease pipeline.
Seamlessly integrating these biotech companies into its portfolio accelerates growth and expands Merck’s market share while limiting hurdles as it enters new markets.
As a result, the Big Pharma mainstay has maintained a five-year average gross margin above 73%.
Those high and expanding margins indicate pricing power and operational efficiency that allow Merck to sustain and grow its dividend, which yields 2.84% (about $3.40 per share annually).
While dividends are common among mature health care companies—particularly large pharmaceutical firms and established managed-care companies—Merck stands out.
The company has raised its payout for 14 consecutive years and posts a five-year dividend growth rate of 5.75%.
How Wall Street Feels About Merck
Based on 18 analysts covering the stock, Merck has a consensus Moderate Buy rating, with 11 analysts assigning MRK a Buy. With an average one-year price target of $127.13, Wall Street sees potential upside of more than 7%.
Institutional ownership remains above average at more than 76%, with inflows of nearly $37 billion exceeding outflows of about $19 billion over the past 12 months. Meanwhile, current short interest of just 1.18% of the float—roughly 29 million of the 2.47 billion shares outstanding—suggests bears are largely keeping their distance.
Merck has been in the green zone on TradeSmith’s financial health indicator for more than six months and scores higher than 93% of the companies evaluated by MarketBeat, ranking 39th out of 858 stocks in the medical sector.
This message is a paid sponsorship from Decentralized Masters, a third-party advertiser of MarketBeat. Why did I get this email?.
If you have questions or concerns about your account, please email our U.S. based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 North Reid Place, Sixth Floor, Sioux Falls, South Dakota 57103. USA..